Candel Therapeutics stock plummets 35% on prostate cancer BLA delay
In short
Shares of Candel Therapeutics dropped sharply by 35% after the company disclosed a delay in its regulatory filing. The setback specifically centers on the Biologics License Application for its prostate cancer candidate. The sudden timeline shift has raised immediate investor concerns regarding the asset's development schedule.
Key points
- Regulatory delays can lead to immediate and severe volatility for clinical-stage biotech…: Regulatory delays can lead to immediate and severe volatility for clinical-stage biotech stocks.
- The revised filing schedule postpones potential approval for the prostate cancer treatmen…: The revised filing schedule postpones potential approval for the prostate cancer treatment.
- Investor sentiment has weakened significantly following the company's regulatory timeline…: Investor sentiment has weakened significantly following the company's regulatory timeline setback.